ATRA stock forecast
Our latest prediction for Atara Biotherapeutics, Inc.'s stock price was made on the Aug. 18, 2020 when the stock price was at 11.92$.
In the short term (2weeks), ATRA's stock price should underperform the market by -2.08%. During that period the price should oscillate between -10.17% and +10.84%.
In the medium term (3months), ATRA's stock price should underperform the market by -6.02%. During that period the price should oscillate between -40.52% and +26.79%.Get email alerts
Create a solid portfolio with ATRA
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.97$ per share.
The book value per share is 9.98$
Three months stock forecastAug. 18, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|